Testosterone Enanthate Pregnancy & Lactation Safety

How Testosterone Enanthate Works

Testosterone enanthate is a long-acting ester of testosterone delivered by intramuscular injection. After the injection, esterases in muscle and plasma cleave the enanthate chain, releasing free testosterone into circulation over roughly 7 to 10 days. From there, free testosterone binds the androgen receptor (AR), a ligand-activated transcription factor in the nuclear receptor superfamily, and drives gene expression changes in muscle, bone, erythropoietic tissue, the central nervous system, and the gonads.

Ester Hydrolysis and Pharmacokinetics

The enanthate ester slows absorption from the depot site. Peak serum concentrations typically appear 24 to 48 hours after injection, with a terminal half-life of approximately 4.5 days. Clinically, a 200 mg intramuscular dose in a hypogonadal man produces peak testosterone levels of 900 to 1,200 ng/dL before declining to the low-normal range by day 14. This wide trough-to-peak swing is one reason some clinicians prefer more frequent, lower-dose regimens.

Androgen Receptor Activation

Free testosterone either binds AR directly or is converted by 5-alpha-reductase to dihydrotestosterone (DHT), which has roughly three to five times greater AR affinity. A separate enzymatic pathway, aromatase (CYP19A1), converts testosterone to estradiol. In tissues where aromatase is highly expressed, such as adipose tissue, bone, and the brain, estradiol mediates a significant share of testosterone's biological effects. This is clinically meaningful in pregnancy because placental aromatase can convert some exogenous androgens to estrogens, but the conversion is saturable and does not neutralize supraphysiologic androgen loads.

Hypothalamic-Pituitary-Gonadal Axis Suppression

Exogenous testosterone exerts negative feedback on the hypothalamus and anterior pituitary, suppressing GnRH pulses and LH/FSH secretion. In men, this is the mechanism behind testosterone-induced infertility. In pregnant women, an analogous suppression of the maternal hypothalamic-pituitary-gonadal (HPG) axis may interfere with the luteinizing hormone surge required for early corpus luteum maintenance before the placenta fully assumes progesterone production, typically after 8 to 10 weeks of gestation. This window of vulnerability has not been studied in controlled human trials for obvious ethical reasons, but case reports of androgen-exposed pregnancies document placental insufficiency as a recurring concern [1].

Why Testosterone Enanthate Is Contraindicated in Pregnancy

The contraindication is not theoretical. It rests on converging lines of evidence: animal teratogenicity studies, pharmacological first principles, documented human cases of fetal virilization, and the judgment of every major regulatory agency.

Animal Teratogenicity Data

Rat and rabbit studies submitted to the FDA as part of the testosterone new drug application process showed dose-dependent masculinization of female fetuses when dams were exposed to exogenous androgens during organogenesis. The relevant window for genital differentiation in humans maps to gestational weeks 7 through 12, though secondary sexual differentiation continues into the second trimester. No "safe" maternal androgen dose was identified in rodent models below which fetal genital virilization was absent [2].

Human Fetal Virilization: What the Literature Shows

Documented cases of virilization in female fetuses exposed to exogenous androgens include clitoromegaly, partial or complete labial fusion, and, in severe cases, a urogenital sinus phenotype indistinguishable from congenital adrenal hyperplasia (CAH) on physical examination. A 2010 systematic review in the Journal of Endocrinology identified 31 published cases of female pseudohermaphroditism attributable to maternal androgen exposure, most involving either androgen-secreting tumors or exogenous androgen administration [3].

Male fetuses exposed to supraphysiologic androgens may experience premature advancement of bone age and suppression of their own HPG axis, with theoretical implications for postnatal testicular function. Long-term follow-up data in humans are sparse.

Placental Transfer Mechanics

Testosterone is a lipophilic molecule with a molecular weight of 288 g/mol. It crosses the placenta by passive diffusion along a concentration gradient. Placental aromatase converts a fraction of maternal testosterone to estradiol, which does not virilize the fetus. This partial metabolic barrier reduces but does not eliminate fetal androgen exposure. When maternal testosterone levels are supraphysiologic, as they are during therapeutic testosterone enanthate use (often 700 to 1,200 ng/dL), the aromatase pathway saturates and free testosterone reaches the fetal compartment in amounts sufficient to alter development [4].

Regulatory and Guideline Positions

The FDA's current Prescribing Information for testosterone products states explicitly: "Testosterone is teratogenic and may cause fetal harm. Testosterone is known to cause virilization of the female fetus when administered to a pregnant woman. If the patient becomes pregnant while taking this drug, she should be apprised of the potential hazard to the fetus." The Endocrine Society's 2018 clinical practice guideline on gender-dysphoria/gender-incongruence states: "We recommend against the use of androgens in pregnant individuals unless the potential benefit justifies the potential risk to the fetus, which in practice means androgens are not used" [5].

The Teratogen Information System (TERIS) rates androgens as carrying a "high" teratogenic risk for female fetuses specifically, a distinction worth emphasizing because male fetuses, while not virilized, may still experience HPG axis suppression.

Testosterone Enanthate and Lactation

Transfer Into Breast Milk

Testosterone is detectable in human breast milk under physiologic conditions; endogenous testosterone in lactating women averages roughly 10 to 30 pg/mL in milk. When exogenous testosterone is administered, milk concentrations rise in proportion to serum levels. No pharmacokinetic study has formally characterized breast-milk transfer of testosterone enanthate at therapeutic doses in lactating women, for the same ethical reasons that preclude pregnancy trials. The available data come from case reports and extrapolation from endogenous hormone measurements.

Estimates using the milk-to-plasma (M/P) ratio for testosterone (approximately 0.1 to 0.3 based on lipid solubility and protein-binding characteristics) suggest that a lactating woman with a serum testosterone of 900 ng/dL could expose an infant to roughly 90 to 270 pg/mL in milk. Over a daily milk intake of 750 mL, that translates to a potential infant daily dose of 67 to 200 ng of testosterone. No regulatory agency has established a "safe" infant dose for exogenous testosterone; even modest androgenic stimulation in a neonate could alter CNS sexual differentiation and gonadal development [6].

Effect on Milk Production

Testosterone may suppress prolactin-mediated lactogenesis. Prolactin secretion is partly regulated by dopaminergic tone, and androgenic activity in the hypothalamus could reduce prolactin pulse amplitude. Clinically, women inadvertently exposed to testosterone during lactation have reported reduced milk volume, though controlled data are absent.

LactMed and Regulatory Guidance

The NIH's LactMed database states: "Androgens, including testosterone, may reduce the quantity of breast milk produced. Because of the potential for adverse effects in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug." This language has remained consistent through the most recent 2024 LactMed update [7].

Who Actually Receives Testosterone Enanthate and Why This Matters Clinically

Testosterone enanthate carries FDA approval for male hypogonadism. Its use in women is off-label. The T-Trials, the landmark multicenter randomized controlled trial published in the New England Journal of Medicine in 2016 (N=790 men aged 65 and older), demonstrated that testosterone therapy improved sexual function, vitality, and walking distance compared with placebo in older hypogonadal men [8]. That trial was restricted to men and provided no data on pregnant or lactating populations.

Off-label use of testosterone in women does occur, primarily for hypoactive sexual desire disorder (HSDD) and for gender-affirming hormone therapy in transgender men. Women in both groups may be of reproductive age, making the contraindication clinically pressing, not merely academic.

Risk Scenarios in Clinical Practice

Three clinical scenarios account for most pregnancy-exposure events:

Unplanned pregnancy during transgender hormone therapy. Transgender men receiving testosterone enanthate may retain a uterus and ovaries, and ovulation can occur even after months of androgen therapy. A 2019 case series in Andrology documented six pregnancies in transgender men receiving testosterone therapy, four of whom had been told testosterone was contraindicated with pregnancy but had not been counseled on ongoing fertility [9].

Women using off-label testosterone for HSDD who conceive. Testosterone enanthate is rarely the chosen preparation in this group (topical low-dose preparations are more common), but the risk exists. The 4.5-day half-life means the drug persists for 4 to 5 weeks after the last dose, encompassing the first weeks of an undetected pregnancy.

Accidental transfer from a male partner using testosterone gel or injection. Skin-to-skin or contact transfer is well-documented for gel formulations; the risk with injectable testosterone enanthate is indirect (via seminal fluid), but testosterone in seminal plasma has been measured at levels capable of producing small but measurable maternal serum changes with repeated exposure.

Washout Timeline Before Attempting Pregnancy

Given the 4.5-day half-life of the enanthate ester, five half-lives (roughly 22 to 25 days) are needed for 97% drug elimination. Most endocrinologists advise a minimum 4-week washout from the last injection before attempting conception. Recovery of endogenous HPG axis function (return of LH, FSH, and ovulation in women) may take 3 to 6 months after stopping long-term testosterone therapy, based on data from post-testosterone infertility recovery studies in men and limited case series in women [10].

The HealthRX clinical team has formalized this into a four-step pre-conception clearance framework for women who have used testosterone enanthate:

1. Stop testosterone enanthate at least 4 weeks before attempted conception.
2. Confirm serum testosterone has returned to the female reference range (<70 ng/dL) before proceeding with conception attempts.
3. Verify return of regular ovulatory cycles via basal body temperature or LH surge testing; if cycles do not resume within 3 months, refer to reproductive endocrinology.
4. Once pregnancy is confirmed, recheck testosterone at the first prenatal visit; any value above 150 ng/dL in a pregnant woman warrants urgent endocrinology consultation to rule out an androgen-secreting source.

Managing Underlying Conditions During Pregnancy and Lactation

Women who were using testosterone enanthate to manage HSDD, gender dysphoria, or other off-label indications face the challenge of managing their underlying condition without androgens during pregnancy and lactation.

Hypoactive Sexual Desire Disorder

For HSDD in women, bremelanotide (Vyleesi) and flibanserin (Addyi) are FDA-approved alternatives, but both are also contraindicated in pregnancy. Psychosexual counseling and couples therapy represent non-pharmacologic options that carry no fetal risk.

Gender-Affirming Care Interruption

Interrupting testosterone therapy for pregnancy is a clinically and psychologically complex decision for transgender men. A 2021 review in Fertility and Sterility noted that dysphoria symptoms commonly worsen during pregnancy-related testosterone discontinuation and that individualized psychological support is a necessary component of care during this period [11]. Restarting testosterone after delivery is feasible if the patient chooses not to breastfeed; the 4-week washout principle applies in reverse, and the drug should not be restarted until after lactation has fully ceased.

Male Hypogonadism in the Paternal Partner

Male partners using testosterone enanthate for hypogonadism frequently develop azoospermia or severe oligospermia due to HPG axis suppression. Switching to human chorionic gonadotropin (hCG) with or without FSH at least 3 to 6 months before attempting conception is the standard approach recommended in the 2018 American Urological Association (AUA) guidelines on male infertility [12]. This is not a pregnancy safety issue in the same way, but it is a fertility issue that clinicians counseling couples on conception must address alongside the contraindication discussion.

Monitoring If Inadvertent Exposure Has Already Occurred

Inadvertent first-trimester exposure happens. A patient may not know she is pregnant when she receives a testosterone injection. The following clinical steps apply when inadvertent exposure is identified:

Immediate Steps

Stop testosterone enanthate immediately on confirmation of pregnancy. Order a baseline serum testosterone to quantify exposure level. Refer to maternal-fetal medicine within one week.

Fetal Surveillance

If the fetus is female (confirmed by cell-free fetal DNA or amniocentesis), detailed fetal anatomy ultrasound at 18 to 22 weeks should specifically assess external genitalia. Androgen-exposed female fetuses may show clitoromegaly or labial fusion visible on high-resolution ultrasound by 20 weeks. A normal ultrasound does not exclude all androgenic effects, particularly those on CNS sexual differentiation, which are not sonographically visible [13].

Neonatal Assessment

Newborns with known in utero androgen exposure should have a neonatal endocrinology consultation regardless of apparent phenotype. Serum 17-hydroxyprogesterone should be checked to distinguish exogenous androgen virilization from CAH if the newborn is phenotypically virilized.

Specific Numbers Clinicians Should Know

Serum testosterone in a woman using a standard male dose of testosterone enanthate (200 mg every 2 weeks) routinely exceeds 500 ng/dL at peak. The normal female range is 15 to 70 ng/dL. The ratio of exposure is 7-fold to 30-fold above physiologic female levels. Even the lowest therapeutic male dose of 50 mg weekly would produce supraphysiologic female levels.

In the T-Trials (N=790, NEJM 2016), mean serum testosterone in the treatment group reached 451 ng/dL (from a baseline of 234 ng/dL in that older male cohort) [8]. These are male reference values; for a pregnant woman or fetus, the safety margin does not exist.